<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/54BE99BE-2718-429B-B851-CF6393F28E98"><gtr:id>54BE99BE-2718-429B-B851-CF6393F28E98</gtr:id><gtr:name>Xstalbio Ltd.</gtr:name><gtr:address><gtr:line1>CIDS, THOMSON BUILDING , UNIVERSITY AVENUE</gtr:line1><gtr:city>GLASGOW</gtr:city><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/54BE99BE-2718-429B-B851-CF6393F28E98" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>54BE99BE-2718-429B-B851-CF6393F28E98</gtr:id><gtr:name>Xstalbio Ltd.</gtr:name><gtr:address><gtr:line1>CIDS, THOMSON BUILDING , UNIVERSITY AVENUE</gtr:line1><gtr:city>GLASGOW</gtr:city><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>47061.0</gtr:offerGrant><gtr:projectCost>104580.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/FB558F5F-BB21-4773-9C7A-65E79D35B239"><gtr:id>FB558F5F-BB21-4773-9C7A-65E79D35B239</gtr:id><gtr:firstName>Marie-Claire</gtr:firstName><gtr:surname>PARKER</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=720585"><gtr:id>F8D9740D-88A7-4E19-84FB-DF73A9236E6C</gtr:id><gtr:title>Concentrating on Better Healthcare</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>GRD Development of Prototype</gtr:grantCategory><gtr:grantReference>720585</gtr:grantReference><gtr:abstractText>XstalBio is a protein medicine formulation and delivery company that seeks to enable better
and more cost effective treatments for patients. The company has developed and patented
technology for converting delicate therapeutic proteins into stable dry powders via a simple,
fast and standardised manufacturing process. Prior to administration the dry protein particles
may be rapidly re-dissolved to very high concentration so that protein drugs can be
conveniently delivered to patients in a single monthly injection and preferably at home.
XstalBio now need to develop a prototype plant that can demonstrate that the dry powders can
be manufactured at a commercial scale safely and reproducibly. A key barrier until now has
been finding a way to test different equipment options for a critical concentration step in the
process because at pilot scale these are not available in a format that can handle processing of
flammable solvents. This project will firstly enable XstalBio to develop an isolator facility
that can be used to exclude oxygen from where the equipment is being tested, thus allowing
the process to be run safely. The next step will be to compare a range of equipment supplied
by vendors for continuously concentrating protein particles at pilot scale to determine which
gives the best overall performance. Finally the selected concentrator will be integrated with
the other process equipment in a fully operational prototype that is designed to be scaled-up
further for manufacture. Once XstalBio has demonstrated a large scale process for preparing
dry protein powders can be carried out safely and cost-effectively and without altering the
potency of the drug, the company intend to compete aggressively for business with more
expensive protein drying options such as freeze-drying or spray drying. In the longer term the
project should lower the cost of medicines for healthcare providers and increase compliance
and convenience for patients.</gtr:abstractText><gtr:fund><gtr:end>2016-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2015-02-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>47061</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">720585</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>